Literature DB >> 2454260

IL-4 inhibits IL-2-mediated induction of human lymphokine-activated killer cells, but not the generation of antigen-specific cytotoxic T lymphocytes in mixed leukocyte cultures.

H Spits1, H Yssel, X Paliard, R Kastelein, C Figdor, J E de Vries.   

Abstract

Human rIL-4 was studied for its capacity to induce lymphokine-activated killer (LAK) cell activity. In contrast to IL-2, IL-4 was not able to induce LAK cell activity in cell cultures derived from peripheral blood. IL-4 added simultaneously with IL-2 to such cultures suppressed IL-2-induced LAK cell activity measured against Daudi and the melanoma cell line MEWO in a dose-dependent way. IL-4 also inhibited the induction of LAK cell activity in CD2+, CD3-, CD4-, CD8- cells, suggesting that IL-4 acts directly on LAK precursor cells. IL-4 added 24 h after the addition of IL-2 failed to inhibit the generation of LAK cell activity. Cytotoxic activity of various types of NK cell clones was not affected after incubation in IL-4 for 3 days, indicating that IL-4 does not affect the activity of already committed killer cells. No significant differences were observed in the percentages of Tac+, NKH-1+ and CD16+ cells after culturing PBL in IL-2, IL-4 or combinations of IL-2 and IL-4 for 3 days. IL-4 also inhibited the activation of non-specific cytotoxic activity in MLC, as measured against K-562 and MEWO cells. In contrast, the Ag-specific CTL activity against the stimulator cells was augmented by IL-4. Collectively, these data indicate that IL-4 prevents the activation of LAK cell precursors by IL-2, but does not inhibit the generation of Ag-specific CTL.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2454260

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  37 in total

1.  Heterogeneity of cytokine functions in HIV infection.

Authors:  S K Kundu; T C Merigan
Journal:  Immunology       Date:  1997-06       Impact factor: 7.397

Review 2.  Regulation of hemopoietic cell development by interleukins 4, 5 and 6.

Authors:  D Rennick; S Hudak; G Yang; J Jackson
Journal:  Immunol Res       Date:  1989       Impact factor: 2.829

3.  Interleukin-2 production of lymphocytes in food sensitive atopic dermatitis.

Authors:  H Agata; N Kondo; O Fukutomi; S Shinoda; T Orii
Journal:  Arch Dis Child       Date:  1992-03       Impact factor: 3.791

Review 4.  Interleukin-4. A regulatory protein.

Authors:  J H Jansen; W E Fibbe; R Willemze; J C Kluin-Nelemans
Journal:  Blut       Date:  1990-05

5.  Interleukin-4 induces the synthesis and secretion of MCP-1/JE by human endothelial cells.

Authors:  B J Rollins; J S Pober
Journal:  Am J Pathol       Date:  1991-06       Impact factor: 4.307

6.  Roles for interleukin-2 (IL-2) and IL-4 in the generation of allocytotoxic T cells in the primary and secondary responses in vitro.

Authors:  H Suzuki; I S Tunru; A Yokoyama
Journal:  Experientia       Date:  1992-03-15

7.  Natural killer cells are a source of interferon gamma that drives differentiation of CD4+ T cell subsets and induces early resistance to Leishmania major in mice.

Authors:  T M Scharton; P Scott
Journal:  J Exp Med       Date:  1993-08-01       Impact factor: 14.307

8.  IL-4 acts as a homeostatic regulator of IL-2-induced TNF and IFN-gamma.

Authors:  C Bello-Fernandez; P Oblakowski; A Meager; A S Duncombe; D M Rill; A V Hoffbrand; M K Brenner
Journal:  Immunology       Date:  1991-02       Impact factor: 7.397

Review 9.  HCV-induced regulatory alterations of IL-1β, IL-6, TNF-α, and IFN-ϒ operative, leading liver en-route to non-alcoholic steatohepatitis.

Authors:  Rabia Nawaz; Sadia Zahid; Muhammad Idrees; Shazia Rafique; Muhammad Shahid; Ammara Ahad; Iram Amin; Iqra Almas; Samia Afzal
Journal:  Inflamm Res       Date:  2017-03-11       Impact factor: 4.575

10.  Cytotoxic T cell lines recognize autologous and allogeneic melanomas with shared or cross-reactive HLA-A.

Authors:  Y Hayashi; D S Hoon; M S Park; P I Terasaki; D L Morton
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.